机构：[1]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]Department of Thoracic Surgery, Zhongshang Hospital, Fudan University, Shanghai China[3]Department of Thoracic Surgery, Anyang Cancer Hospital, Anyang, China[4]Department of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[5]Department of Thoracic Surgery, Linxian Renmin Hospital, Linxian, China[6]Department of Thoracic Surgery, Linxian Cancer Hospital, Linxian, China[7]Department of Thoracic Surgery, The Fourth Military University Hospital, Xian, China[8]Department of Thoracic Surgery, Sichuan Cancer Hospital, Chengdu, China外科中心胸外科中心四川省肿瘤医院胸外科[9]Department of Thoracic Surgery, Liaoning Cancer Hospital, Shenyang, China[10]Department of Thoracic Surgery, The Fourth Hospital, Shijiazhuan, China[11]Department of Thoracic Surgery, Jining Medical school Hospital, Jining,China[12]Department of Thoracic Surgery, Fujian Cancer Hospital, Fujian Medical University, Fuzhou, China[13]Department of Thoracic Surgery, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院[14]Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai, China[15]Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China四川大学华西医院[16]Department ofThoracic Surgery, The First AffiliatedHospital, Zhongqing MedicalUniversity, Zhongqing,China[17]Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, China[18]Department of Thoracic Surgery, Beijing cancer hospital, Beijing University, Beijing, China[19]Department of Thoracic Surgery, Linxian Esophageal Cancer Hospital, Linxian, China[20]Department of Thoracic Surgery, Jiangsu Renmin Hospital, Nanjing, China[21]Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[22]Department of Thoracic Surgery, Sun Yat-sen University Cancer Center Guangzhou, China[23]Department of Thoracic Surgery, Fujian Medical University Hospital, Fuzhou, China[24]Department of Thoracic Surgery, Heilongjiang Cancer Hospital, Harbin, China[25]Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, China[26]Department of Thoracic Surgery, Tianjin Cancer Hospital, Tianjin, China[27]Department of Thoracic Surgery, First Affiliated Hospital, Zhejiang University, Hangzhou, China浙江大学医学院附属第一医院[28]Department of Thoracic Surgery, Jiangsu Cancer Hospital, Nanjing, China[29]Department of Thoracic Surgery, Dept of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong
Esophageal cancer has a high incidence among malignancies in China, but a comprehensive picture of the status of its surgical management in China has hitherto not been available. A nationwide database has recently been established to address this issue.A National Database was setup through a network platform, and data was collected from 70 high-volume centers (>100 esophagectomies/per year) across China. Data was entered between January 2009 and December 2014, and was analyzed in June 2015 after a minimal follow-up of 6 months for all patients. 8181 patients with complete data who received surgery for primary esophageal cancer on the Database were included in the analysis.In this series, there were 6052 males and 2129 females, with a mean age of 60.5 years (range: 22-90 years). The pathology in 95.5% of patients was squamous cell carcinoma. The pathological stage distribution was 1.2% in stage 0, 2.5% in Ia, 11.5% in Ib, 14.8% in IIa, 36.1% in IIb, 19.3% in IIIa, 8.3% in IIIb, 6.2% in IIIc. 1800 patients (22.0%) with locally advanced disease received preoperative neoadjuvant therapy and 3592 patients (43.9%) underwent postoperative adjuvant chemotherapy and/or radiotherapy. The esophagectomies were performed through left thoracotomy approach in 5870 cases (72.6%), through right chest approach in 2215 cases (27.4%) including right thoracotomy (21.3%) and VATS (6.1%). The 30-day postoperative mortality rate was 0.6% (43 patients), and the overall postoperative complication rate was 11.6% (951 patients). The 1-, 3-, and 5-year overall survival rates were 82.6%, 61.6%, and 52.9%, respectively.This National Registry Database from high-volume centers provides a comprehensive picture of surgical management for esophageal cancer in China for the first time. Squamous cell carcinoma predominates, but there is heterogeneity with respect to the surgical approach and perioperative oncologic management. Overall, surgical mortality and morbidity rates are low, and good survival rates have been achieved due to improvement of surgical treatment technology in recent years.
基金：
This work is supported by grants from National Science and Technology Support Program (2015BAI12B08, You-Sheng Mao).
第一作者机构：[1]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
通讯作者：
通讯机构：[1]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[*1]Department of Thoracic Surgery,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
推荐引用方式(GB/T 7714)：
Y.-S.Mao,S.-G. Gao,Q.Wang,et al.Analysis of a registry database for esophageal cancer from high-volume centers in China.[J].DISEASES OF THE ESOPHAGUS.2020,33(8):doi:10.1093/dote/doz091.
APA：
Y.-S.Mao,S.-G. Gao,Q.Wang,X.-T. Shi,Y. Li...&J. He.(2020).Analysis of a registry database for esophageal cancer from high-volume centers in China..DISEASES OF THE ESOPHAGUS,33,(8)
MLA：
Y.-S.Mao,et al."Analysis of a registry database for esophageal cancer from high-volume centers in China.".DISEASES OF THE ESOPHAGUS 33..8(2020)
